The dried flower buds of Magnolia biondii Pamp (herbal name, Xin-Yi) are a traditional Chinese medicine with a long history of clinical use in the treatment of allergic rhinitis and sinusitis. However, the constituents responsible for its antiallergic effects remain unidentified. In the present study, a novel bisepoxylignan, isoeudesmin (1), and eight known bisepoxylignans, pluviatilol (2), eudesmin (3), magnolin (4), lirioresinol-B dimethyl ether (5), epimagnolin B (6), kobusin (7), aschantin (8), fargesin (9), were isolated from effective fractions through antiallergic bioassay-guided procedures using mouse bone marrow-derived mast cells (BMMCs) and IgE-induced passive cutaneous anaphylaxis mice. The compound structures were elucidated through nuclear magnetic resonance and mass spectrometry analyses. Compound 1 and compounds 2-6 and 9 exhibited antiallergic effects without affecting the viability of BMMCs. Compounds 2 and 9 showed the strongest effects with IC 50 values of 52.18 and 93.03 mM, respectively. In this paper, the structure-activity relationship between these bisepoxylignans and their antiallergic effects is discussed. After evaluating the intensity of the antiallergic effects of the extracts, further separating the fractions, and isolating the purified compounds, we concluded that biosepoxylignans are the main constituents in Xin-Yi contributing to its anti-allergic efficacy.
Introduction
Magnolia biondii Pamp of the family Magnoliaceae is mainly distributed in Henan, China. 1 The dried ower buds of Magnolia biondii Pamp (herbal name, Xin-Yi) are among the most commonly used herbs in Chinese medicine. They have a long history of clinical use in the treatment of allergic diseases. 2, 3 In ancient China, Xin-Yi was reported to be efficacious in the treatment of cutaneous pruritus (recorded in the book Solar Corona Medicine, published in 900 A.D.), allergic rhinitis, and sinusitis (recorded in the book Austroyunnanese Medicine, published in 1300 A.D.). The antiallergic effects of Xin-Yi have also been reported in some prescriptions in ancient China. For example, Xanthium pulvis, XinQin decoction, and Xin-Yi decoction, which are mainly composed of Xin-Yi, were used in the treatment of allergic rhinitis, sinusitis, and asthma. These prescriptions are still used in clinical medicine today. 4 Animal experiments have conrmed that these prescriptions exert their antiallergic effects by inhibiting the degranulation of mast cells, 5 alleviating homologous passive skin anaphylaxis, and suppressing histamine-induced metatarsal swelling in rats. 6, 7 A clinical study reporting on the effects of Xin-Yi decoction in 40 patients with allergic asthma showed that patients who received the treatment exhibited improved pulmonary function and vital capacity, and their forced expiratory volume 1 (FEV 1 ) and FEV 1 % were more signicantly altered (P < 0.01) than those in a group of controls, indicating that Xin-Yi is highly effective in the treatment of allergies.
8 Therefore, determining the exact constituents responsible for its antiallergic effects requires additional research.
Phytochemical research has revealed that Xin-Yi is a prolic source of bisepoxylignans, which exhibit a broad range of biological activities, 9 such as anti-inammatory, 10 antioxidant, antimicrobial, anticancer, and antiplatelet activities as well as liver protection.
11 Recent studies have revealed that various types of lignans, such as gomisin N (dibenzocylooctadiene lignan), mesodihydroguaiaretic acid (dibenzylbutane lignan), and pinusthunbergiside A (benzodioxane lignan), [12] [13] [14] exert their antiallergic effects by suppressing mast cell activation. Bisepoxylignans from the stems of Lindera obtusiloba Blume were reported to play a crucial role in antiallergic inammation through the suppression of A23187 -stimulated human mast cell degranulation.
15 Among a bioactive screen of 95% ethanol isolated the puried compounds by using an acknowledged antiallergic test model-the mouse bone marrow-derived mast cell (BMMC) degranulation test-and the passive cutaneous anaphylaxis (PCA) mice model. We obtained one novel bisepoxylignan, isoeudesmin (1), and eight known biosepoxylignans, pluviatilol (2), eudesmin (3), magnolin (4), lirioresinol-B dimethyl ether (5), epimagnolin B (6), kobusin (7), aschantin (8) , and fargesin (9) (Fig. 1A) , through bioassayguided isolation procedures. The bioassay results revealed that compound 1 and compounds 2-6 and 9 exerted inhibitory effects on BMMC degranulation and tumour necrosis factor a (TNF-a) expression. Furthermore, we also discussed the structure-activity relationship between these bisepoxylignans and their antiallergic effects. The results indicated that biosepoxylignans, as the main constituents in Xin-Yi contribute to its antiallergic efficacy.
Experimental section
General experimental procedures IR spectra were obtained using a Nicolet-Magna-750-FTIR spectrometer (KBr pellets) (Thermo Fisher 
BMMC culture
BMMCs were derived from the bone marrow of BALB/c mice. Cells were maintained in RPMI-1640 medium (Gibco) supplemented with 50 mM 2-mercaptoethanol (Sigma-Aldrich), 1 mM sodium pyruvate, 100 U per mL penicillin/100 mg mL À1 streptomycin, 0.1 mM nonessential amino acids, 25 mM N-2-hydroxyethylpiperazine-N-2 0 -ethanesulfonic acid (HEPES), 10%
foetal bovine serum, and 10 ng mL À1 mouse recombinant interleukin-3 (PeproTech, Rocky Hill, NJ, USA). Cells were fed every 5 days. Aer 4 weeks, cell purity was assessed by measuring CD117 and Fc3RI expression levels though ow cytometry. Of the cells, 99% were double-positive for CD117 and Fc3RI.
Cell viability analysis using XTT assay
BMMCs were dispensed into 96-well plates (5 Â 10 4 cells per well) and treated with the isolated compounds (100 mM) for 24 h, and cell viability was assessed using a 2.3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanilide salt (XTT)-based cell proliferation assay (Life Technologies, Mannheim, Germany), following the manufacturer's instructions. Cell viability is expressed as the percentage of OD test relative to OD control , where OD test is the optical density of cells exposed to compounds (test samples), and OD control is the optical density of the control samples.
Degranulation assay
First, BMMCs at 5 Â 10 5 cells per mL were incubated with 0.5 mg Finland) . The amount of total b-hex released was calculated using the following formula: % release ¼ 100 Â supernatant absorbance/ (supernatant absorbance + pellet absorbance).
Cytokine enzyme-linked immunosorbent assay
BMMCs were dispensed into 48-well plates (1 Â 10 5 cells per well) and sensitised with 0.5 mg mL À1 anti-DNP-IgE for 24 h. The isolated compounds were dissolved in media containing 0.1% dimethyl sulfoxide and added to the cells to obtain a nal concentration of 100 mM for 30 min. Cells were stimulated with DNP-BSA for 24 h for TNF-a expression. The supernatant was collected, centrifuged at 300 Â g for 5 min to remove any cell debris, and stored at À80 C until ELISA analysis. The supernatant was analysed for TNF-a expression using ELISA kits (eBioscience), following the manufacturer's instructions. humidity of 50% to 60%. The animals were allowed free access to food and water and allowed to acclimatize for at least 7 days before the experiments. IgE-induced PCA was performed as described previously.
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Briey, 1 mg anti-DNP-IgE was intradermally injected into the right ear of 7 week old male mice. The next day, the mice received oral administration of 100 mg kg À1 Frs. E5 and E6 (in that order) or 50 mg kg À1 Ketotifen fumarate salt (SigmaAldrich). Aer 1 hour, the mice were challenged for 30 min by intravenous injection of 100 mg of DNP-HSA in 300 mL saline containing Evans blue (0.5%). Finally, Evans blue was extracted aer 24 h at room temperature with 300 mL of formanide and measured by absorbance at 630 nm.
Statistical analysis
Experiments were conducted in triplicate. Values are presented as the mean AE standard error of the mean. Signicant differences were determined using the Student t test with the level of signicance set at *P # 0.05, **P # 0.01, and ***P # 0.001.
Results and discussion
The EtOAc-soluble portion of the 95% EtOH extract of Xin-Yi was puried separately by column chromatography over MCI gel, silica gel, reversed-phase C 18 silica gel, Sephadex LH-20, and by preparative HPLC, yielding six fractions and nine compounds, including one novel biosepoxylignan (1) and eight known biosepoxylignans (2-8) (see Extraction and isolation). According to the effect of 95% EtOH extract on the allergic mouse model, 16 we examined the effects of 95% EtOH extract on BMMC degranulation. The results revealed that 95% EtOH extract exerted a weak antiallergic effect; it inhibited b-hex release by 22 (Fig. 2) . In particular, Frs. E5 and E6 inhibited b-hex release by up to 65.5% and 85.6% relative to that of the control, respectively. Based on the in vitro results, we evaluated the antiallergic activity of Frs. E5 and E6 in a PCA model. As shown as Fig. 3 , the colour in the ear of Frs. E5 and E6 group became lighter than that of the model group. Additionally, Frs. E5 and E6 signi-cantly reduced the dye extravasations by 26.15% (P < 0.05) and 38.94% (P < 0.001), respectively. These results suggest that Frs. E5 and E6 exert in vivo antiallergic effects by suppressing mast cell activation.
Next, nine compounds were obtained from the active Frs. E5, and E6, namely isoeudesmin (1), pluviatilol (2), 18 eudesmin (3), 19 magnolin (4), 20 lirioresinol-B dimethyl ether (5), 21 epimagnolin B (6), 20 kobusin (7), 20 aschantin (8), 22 and fargesin (9) . 20 23 NOSY revealed that H-1, 5 and H-2, 6 were unrelated and also conrmed that compound 1 was a symmetrical bisepoxylignan (Fig. 1A) . Therefore, the absolute conguration of compound 1 was determined, and it was named "isoeudesmin".
Next, the antiallergic effects of compounds 1-9 obtained from Frs. E5 and E6 extracts on BMMC degranulation were evaluated. Results revealed that compounds 1-6 and 9 at 100 mM reduced the b-hex release without affecting the BMMC viability (Fig. 4A) . In addition, treatment of BMMCs with compounds 2 and 9 for 30 min suppressed the b-hex release in a dose-dependent manner; the inhibition was up to 67.8% and 46.5% relative to the control, respectively (Fig. 4B) . Furthermore, compounds 2 and 9 were the most effective one, with IC 50 values of 52.18 and 93.03 mM, respectively.
TNF-a, produced by activated BMMCs, mediates many physiological processes of allergic inammation; therefore, we determined the effect of isolated compounds on TNF-a expression. We incubated BMMCs with 0.5 mg mL À1 anti-DNP-IgE and 100 mM isolated compounds for 30 min and subsequently stimulated them with 0.1 mg mL À1 DNP-BSA for 24 h.
Compounds 1-6 and 9 considerably inhibited TNF-a expression (Fig. 5 ). In particular, compounds 2 and 9 suppressed TNFa expression by up to 55.9% and 68.1%, respectively. Thus, the present study determined the constituents responsible for the antiallergic effects of Xin-Yi.
On the basis of the antiallergic effects of compounds 1-6 and 9, we demonstrated the differences in the effects of the main active Frs. E5 and E6. The HPLC ngerprints (Fig. 1B) revealed that Fr. E5 mainly contains compounds 1-8, and Fr. E6 mainly contains compounds 7-9. In addition, compounds 2 and 9 exerted the strongest antiallergic effects among the nine compounds. Fr. E6 exerted stronger effects than did Fr. E5, because compound 9 was a main constituent in Fr. E6, and compound 2 was merely a microconstituent in Fr. E5. The agreement of results on the antiallergic effects between the fractions and puried compounds illustrates the feasibility of our bioassay-guided isolation procedure. Bisepoxylignans are present in large quantities (total content of compounds 3-5, 8, and 9 up to 5%) in Xin-Yi, 24 indicating that they are the main bioactive constituents responsible for Xin-Yi's antiallergic This journal is © The Royal Society of Chemistry 2017 efficacy; however, the intensity of these bisepoxylignans was moderate.
Finally, because of the similarity between the structures of compounds 1-9 and marked differences in their antiallergic effects, we can discuss the structure-activity relationship between these bisepoxylignans and antiallergic effects (Fig. 6) . First, a greater number of methoxyl groups in the benzene ring was associated with a reduced antiallergic effect, as evidenced by the comparison of the antiallergic effects of compounds 2 and 3 with those of compounds 4, 5, 7, and 8. Second, compounds 7 and 8 exerted weaker antiallergic effects than did compounds 3 and 4, indicating that the methylenedioxy group reduced the activity. Third, substitution of the hydroxyl group with a methoxyl group in the benzene ring, such as in compounds 7 and 8, reduced the antiallergic effects compared with those of compound 2, suggesting that hydroxyl to methoxyl substitution reduces the antiallergic activity. Fourth, symmetrical bisepoxylignans, namely compounds 1, 3, 4, 5, 7, and 8, exerted substantially weaker antiallergic effects compared with those of the asymmetrical bisepoxylignans, namely compounds 6 and 9, indicating that the stereochemical structure of the compounds is crucial to their antiallergic activity. This nding is consistent with a previous study on the antiallergic activity of bisepoxylignans.
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Conclusions
In conclusion, nine bisepoxylignans, including one novel compound, were obtained through antiallergic bioassay-guided isolation using in vitro and in vivo models. The proposed compound (isoeudesmin) and known compounds (pluviatilol, eudesmin, magnolin, lirioresinol-B dimethyl ether, epimagnolin B, and fargesin) obtained from Xin-Yi inhibited BMMC degranulation and TNF-a expression, contributing to Xin-Yi's antiallergic effect. Moreover, bisepoxylignans can be considered candidates for antiallergic agents derived from Xin-Yi.
